Advertisement

PREDICTORS OF CHOLINESTERASE INHIBITOR AND MEMANTINE USE IN NEWLY ADMITTED NURSING HOME RESIDENTS WITH DEMENTIA AND/OR COGNITIVE IMPAIRMENT: IMPACT OF DRUG POLICIES IN SASKATCHEWAN AND ONTARIO, CANADA

      Varying prevalence of cholinesterase inhibitor (ChEI) and memantine use has been documented across jurisdictions, likely driven by population characteristics but also by reimbursement policies. Coverage is often not provided for persons with more severe cognitive impairment, those who show deterioration while receiving the medications, and those on contraindicated medications. We compared patterns and predictors of ChEI/memantine use at admission to nursing homes in Saskatchewan and Ontario, Canada, two provinces with differing reimbursement policies.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'